EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

The FDA has granted approval for the IND application of Everest Medicines’ tumour-associated antigen (TAA) vaccine, EVM14.

The FDA has cleared Everest Medicines’ Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

EVM14 is Everest's first internally developed mRNA therapeutic vaccine to receive FDA IND approval, marking a significant milestone in the Company's efforts to develop innovative mRNA therapeutics ...